The recent biotech market downturn raised the bar for going public. Unlike the 2020-2021 period where preclinical companies IPO'd, today's successful offerings are from companies with mid-to-late-stage clinical programs. This de-risked profile is necessary to attract both specialist and crucial generalist investors back to the sector.

Contrary to the challenging macroeconomic environment, the biotech sector is experiencing a robust financial market. Leading indices are up double digits, and April 2026 was the most active IPO month in five years, signaling strong investor confidence in the industry's long-term potential.

Unlike the 2020-2022 bubble, the expected wave of biotech IPOs features mid-to-late-stage companies with de-risked assets. The market's recent discipline, forced by a tough funding environment, has created a backlog of high-quality private companies that are better prepared for public markets than their predecessors.

Despite predictions of a difficult second quarter, the biotech IPO market has shown surprising strength. Multiple newly public companies have posted strong gains, with one up 500% in three months, signaling robust investor confidence and a receptive market for biotech flotations.

The reopening of the biotech IPO market is fragile. A key risk identified by investors is a series of failed IPOs, which could halt the sector's positive momentum. Consequently, there is intense pressure on bankers and VCs to exhibit "quality discipline," ensuring that only the most mature and high-potential companies go public first to build a track record of success.

The current IPO window sees companies with significant clinical data going public. The previously closed market forced them to advance programs with private funding, resulting in higher-quality offerings compared to the pre-clinical companies that IPO'd during the last boom.

The 2026 biotech IPO market is outpacing 2025, but the focus on companies with late-stage clinical data, like Cardigan, indicates a mature and rational market rather than the speculative, preclinical bubbles of the past.

The successful, upsized IPOs of several biotechs suggest the market is receptive but cautious. Investors are prioritizing companies with lower-risk propositions, such as those building on validated biological mechanisms or advancing into late-stage trials, over purely speculative, early-stage science.

The profile of a company prepared to go public has matured significantly. Unlike the 2020 boom where IND acceptance was a key milestone, today's IPO candidates typically need Phase 2 or even Phase 3 data, raising the quality bar but shrinking the potential pool of companies.